Surface contamination with and personnel exposure to antineoplastic agents before and after the implementation of a closed-system protective device were studied. Samples were collected before and six months after implementation of PhaSeal, a closed-system device for limiting exposure to antineoplastic agents during preparation and administration. Personnel exposure was evaluated by collecting 24-hour urine samples from pharmacists, pharmacy technicians, and nurses working full-time in a chemotherapy drug infusion center and pharmacy. Surface contamination was assessed by wiping potentially exposed surfaces. Both types of samples were analyzed for cyclophosphamide and ifosfamide by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. All 17 wipe samples collected before implementation of PhaSeal had detectable levels of cyclophosphamide, and 11 were positive for ifosfamide. Six months after system implementation, 7 of 21 wipe samples had detectable levels of cyclophosphamide and 15 were positive for ifosfamide. Of eight employees who provided urine samples, six were positive for cyclophosphamide and two for ifosfamide before implementation, and none were positive for either drug after implementation. The PhaSeal system appeared to reduce exposure of health care personnel to cyclophosphamide and ifosfamide.

 

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Hoppe-Tichy Current challenges in European oncology pharmacy practice Journal of Oncology Pharmacy Practice, March 1, 2010; 16(1): 9 - 18. [Abstract] [PDF]

				J. Siderov, S. Kirsa, and R. McLauchlan Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device Journal of Oncology Pharmacy Practice, March 1, 2010; 16(1): 19 - 25. [Abstract] [PDF]

				E. Green, M. Johnston, M. Trudeau, L. Schwartz, S. Poirier, G. Macartney, and D. Milliken Safe Handling of Parenteral Cytotoxics: Recommendations for Ontario J. Oncol. Pract, September 1, 2009; 5(5): 245 - 249. [Abstract] [Full Text] [PDF]

				J. Yoshida, G. Tei, C. Mochizuki, Y. Masu, S. Koda, and S. Kumagai Use of a Closed System Device to Reduce Occupational Contamination and Exposure to Antineoplastic Drugs in the Hospital Work Environment Ann. Hyg., March 1, 2009; 53(2): 153 - 160. [Abstract] [Full Text] [PDF]

				Section 1 Introduction Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 3 - 6. [PDF]

				Section 7 Special devices Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 27 - 30. [PDF]

				Section 10 Chemical contamination monitoring Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 44 - 48. [PDF]

				T. H. Connor and M. A. McDiarmid Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings CA Cancer J Clin, November 1, 2006; 56(6): 354 - 365. [Abstract] [Full Text] [PDF]

				B. R. Harrison, B. G. Peters, and M. R. Bing Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1736 - 1744. [Abstract] [Full Text] [PDF]

				ASHP Guidelines on Handling Hazardous Drugs Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1172 - 1191. [Full Text] [PDF]

				P. Bonnabry, L. Cingria, M. Ackermann, F. Sadeghipour, L. Bigler, and N. Mach Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process Int. J. Qual. Health Care, February 1, 2006; 18(1): 9 - 16. [Abstract] [Full Text] [PDF]

				T. H. Connor, P. J. M. Sessink, B. R. Harrison, J. R. Pretty, B. G. Peters, R. M. Alfaro, A. Bilos, G. Beckmann, M. R. Bing, L. M. Anderson, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 475 - 484. [Abstract] [Full Text] [PDF]